Skip to main content
Clinical Trials/NCT07243873
NCT07243873RecruitingNot Applicable

Synthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter Study

Shanghai Pulmonary Hospital, Shanghai, China5 sites in 1 country10,000 target enrollmentStarted: December 1, 2025Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
10,000
Locations
5
Primary Endpoint
Structural similarity

Study Overview

Brief Summary

This study aims to synthesise PET data that preserves biological relevance and adds clinical value to the diagnosis and prognosis of lung cancer by establishing anatomical-to-metabolic mapping based on paired diagnostic CT and FDG-PET scans, thereby prospectively validating the clinical utility of the model.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 85 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patients with non-small cell lung cancer scheduled to undergo PET-CT and pathological examinations;
  • •Voluntarily participate and sign an informed consent form;

Exclusion Criteria

  • •History of other malignant tumours;
  • •Image artefacts;
  • •Without pathological diagnostic information;
  • •Without paired CT and FDG-PET scan images.

Outcomes

Primary Outcomes

Structural similarity

Time Frame: 2025.12.1-2026.12.1

This is a core outcome measure evaluating the degree of resemblance between the structural characteristics of synthetic PET images and reference PET images. It reflects whether the synthetic PET retains the key structural information of the original image, which is a fundamental indicator for confirming the structural relevance of synthetic PET.

Peak Signal-to-Noise Ratio (PSNR)

Time Frame: 2025.12.1-2026.12.1

A commonly used objective evaluation index in image quality assessment, calculated based on the mean square error between the synthetic PET image and the reference image. It quantifies the ratio of the maximum possible signal value in the image to the noise power that affects image quality. Higher PSNR values indicate that the synthetic PET image has less noise interference and better consistency with the reference image in terms of signal characteristics, thereby reflecting better retention of structural information.

Structural Similarity Index (SSIM)

Time Frame: 2025.12.1-2026.12.1

An index designed to simulate human visual perception to evaluate image structural similarity, which comprehensively considers three aspects: brightness, contrast, and structural consistency between the synthetic PET image and the reference image. The value range is between 0 and 1; a value closer to 1 means that the synthetic PET image has a higher degree of structural consistency with the reference image, indicating that the structural relevance is well retained.

Metabolic Parameter Consistency

Time Frame: 2025.12.1-2026.12.1

A key outcome measure for verifying the biological relevance of synthetic PET, which evaluates whether the metabolic characteristic parameters derived from synthetic PET are consistent with those from reference PET. Metabolic parameters are directly related to the biological functions of tissues/organs, so their consistency is crucial to ensuring that synthetic PET can be used for accurate biological activity assessment.

Secondary Outcomes

  • predictive performance(2025.12.1-2026.12.1)

Investigators

Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Chang Chen

Chief Physician

Shanghai Pulmonary Hospital, Shanghai, China

Study Sites (5)

Loading locations...

Similar Trials

Recruiting
Not Applicable
Added value of digital PET in (re)staging patients with pancreatic cancerpancreatic cancer, response assesment, digital PET
NL-OMON22880Isala hospital, Zwolle, the Netherlands40
Recruiting
Not Applicable
ate PET/CT acquisition for improved tissue characterization and assessment of treatment response: prospective data collection in clinically indicated examinations in oncology.Malignant neoplasm, without specification of siteMalignant neoplasm of oesophagusMalignant neoplasm of accessory sinusesC85C81C61C80C15C31C32C33C34C21C20C22.1C43Other and unspecified types of non-Hodgkin lymphomaMalignant neoplasm of prostateMalignant neoplasm of larynxMalignant neoplasm of tracheaMalignant neoplasm of bronchus and lungMalignant neoplasm of anus and anal canalMalignant neoplasm of rectumIntrahepatic bile duct carcinomaMalignant melanoma of skinHodgkin lymphoma
DRKS00027307niversitätsklinikum Tübingen600
Withdrawn
Phase 1
A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide to Correlate With Response to Anti-Cancer TherapyAdvanced Cancers
NCT02193672M.D. Anderson Cancer Center
Recruiting
Not Applicable
A Multicenter Study Evaluating the Diagnostic Value of 68Ga-MY6349 PET/CT for Prostate CancerPositron-Emission Tomography(PET)Trophoblast Cell Surface Antigen 2Prostate Cancer
NCT06696326The First Affiliated Hospital of Xiamen University100
Completed
Phase 1
A PET (positron emission tomography) clinical research study using prostate specific membrane antigen (PSMA) targeted tracer, 89Zr-Df-IAB2MProstate cancer / Urothelial carcinoma / Renal cell carcinoma / Testicular cancer
JPRN-UMIN000015356niversity of Tsukuba15